Costing and outcomes data for various cancer cohorts using administrative databases in Ontario – Part III (Mantle Cell Lymphoma)

Summary

Client: HOPE Research Centre, Sunnybrook Research Institute

Project ID: P2022-114/2023 0970 348 000

Research Question/Objectives: Mantle cell lymphoma (MCL) is a rare and aggressive form of non-Hodgkin lymphoma (NHL), primarily affecting B-lymphocytes. It is often diagnosed at an advanced stage and has a poor prognosis since it responds poorly to treatment. Even if initial treatment is successful, almost all patients eventually relapse. Disease severity significantly increases in a relapsed setting where sequential therapy is less effective, leading to poorer outcomes and higher mortality rates. In addition to disease stage, MCL can be graded based on whether it is indolent (low-grade) or aggressive (high-grade), and standard management of indolent MCL includes active surveillance (e.g., routine examination and diagnostic imaging).

Objectives:

Primary Objective:

To describe MCL treatment patterns by line of therapy and categorical type of therapy received per line

Secondary Objectives:

To describe annual incidence of MCL
To describe clinical and demographic characteristics of patients diagnosed with MCL
To describe overall survival (OS) of patients with MCL, from diagnosis to death, overall and by categorical treatment sequence
To describe OS of patients with MCL, from time of treatment initiation to death, by line of therapy and categorical type of therapy per line
To describe direct healthcare resource utilization (HCRU) and costs following diagnosis with MCL, overall, and by line of therapy and categorical type of therapy per line

Exploratory Objectives: